INTRODUCTION
============

Endre Mester first observed that mice treated with lasers during experiments investigating the potential carcinogenic effects of laser exposure regrew hair in shaved areas significantly faster than unexposed mice in 1967 [@b1],[@b2]. Other investigators subsequently observed that some patients exhibited paradoxical hair growth at the periphery of areas treated with lasers for hair removal or adjacent to lesions treated with laser sources [@b3]--[@b5]. These seminal observations stimulated others to investigate the potential effects and applications of low level laser (light) therapy (LLLT) in male and female pattern androgenetic alopecia [@b6]--[@b15].

We have previously reported the results of the male arm of a randomized controlled trial that was undertaken to define the safety and physiologic effects that occur when the hair follicle and surrounding tissue structures of the human scalp are exposed to LLLT using a bicycle helmet type device fitted with an array of laser and LED light sources operating at 655 nm [@b16]. This laser system meets the requirements of an FDA Class 3R laser product, and as a non-medical laser system (RDW). The LED components are non-classified light sources when marketed for cosmetic applications, as is the case here. The device was granted an FDA 510k clearance for the treatment of males with Hamilton--Norwood IIa-V, or frontal patterns of hair loss, in patients with Fitzpatrick I--IV skin types based on the results for the male cohort of that trial [@b16],[@b17].

The present investigation reports the results obtained for the female cohort of subjects treated under the TH655 study protocol.

MATERIALS AND METHODS
=====================

A clinical study was conducted as per the IRB approved TH655 protocol (Essex IRB, Lebanon, NJ). The trial was registered on [www.ClinicalTrials.gov](www.ClinicalTrials.gov) and was assigned the identifier NCT01437163. Forty-seven healthy female volunteers 18--60 years old were recruited at two IRB approved treatment sites.

Informed consent was obtained, and each female subject was screened to verify that she met the inclusion and exclusion criteria for the study. History and physical examinations were conducted. All 47 women had Fitzpatrick skin types I--IV and Ludwig--Savin Baldness Scale I--II (L-S I-2, I-3, I-4, II-1, II-2) baldness patterns. An area of scalp was selected in a transition zone at the vertex of the scalp at a site determined by the investigator. The hairs within the selected site were trimmed to a maximum height of 3 mm in area that was approximately 2.5 cm in diameter. The area was marked with a medical tattoo using green ink using aseptic technique.

The site was then photographed using a custom camera apparatus that consisted of a Canon Rebel T3i 18 Megapixel camera system (Canon USA, Melville, NY) equipped with a Tamron 60 mm f/2 Macro lens with 1:1 magnification (Tamron USA, Commack, NY). A 55 mm Lens attachment ring was used to affix a Promaster RL60 LED Ring Light (Promaster, Inc, Fairfield, CT). The camera system was mounted to a custom Stand-off device which was manually positioned onto the scalp surface by the investigator each time photographs were taken. Images were taken positioning the tattoo in the center of the frame. These baseline images were coded and then forwarded to the photographic consultant. The photographic consultant verified that the images were of acceptable quality and processed the images for transmission to the investigator responsible for conducting the hair counts. The transmitted images were masked using a black mask to produce a 1.9 cm diameter circle centered on the tattoo, which provided a consistent 2.85 cm^2^ area for hair counts. Neither the photographic consultant nor the investigator performing the hair counts was aware of the identity of the subject or the subjects\' study group assignment.

Subjects were randomly assigned to active treatment or placebo treatment groups. Each subject received a numbered "TOPHAT655" unit (Apira Science, Inc, Boca Raton, FL) which was distributed to her by the Project Manager, who also provided instructions for the care and use of the device. The patients, the treating physicians, the photographic consultant, and the investigator performing the hair counts were not aware whether the device was a therapeutic (active) device or a functioning placebo (sham). The investigational devices did not have corporate logos or other identifiers, with the exception of a study investigational device number. A serial number was assigned to each helmet, which was recorded in a device log that contained the reference code for placebo and actual test unit. This log was not revealed to any investigator, subject, office staff, hair counter or sponsor employee.

The active treatment group received a "TOPHAT 655" unit containing 21, 5 mW laser diodes and 30 LEDS both operating at 655 nm (655 ± 5 nm and 655 ± 20 nm, respectively) and providing constant illumination over the scalp under the apparatus. Each subject self-treated at home for 25 minutes per treatment session every other day for 16 weeks (60 treatments, 67 J/cm^2^ delivered irradiance, and 2.9 J per treatment session).

The sham group received a unit that was identical in appearance and function to the laser group devices, with the exception that the light sources were incandescent wheat lights that were painted red to mimic the appearance and configuration of the functioning device. Each subject in the sham group self-treated at home for 25 minutes/treatment, every other day for 16 weeks (60 treatments). Incandescent sources were substituted 1:1 for each laser diode and LED source position on the sham helmet\'s interior.

The light output of the active treatment and sham treatment devices was determined using an Ophir Nova Display Power Meter equipped with a Model 30A-P-R-SH detector head (Ophir-Spiricon, LLC, Logan, UT). The active devices delivered an energy density of 67 J/cm^2^ at 655 nm per 25 minute treatment session at the level of the scalp. The placebo units delivered no measurable light at scalp level. The active device design was such that constant illumination was delivered over the areas of the scalp covered by the device.

The operating temperatures of the active and placebo devices were matched and were measured using a Klein Tools Model IR 3000 Thermometer (Klein Tools, Lincolnshire, IL). The temperature of the units was 27.8 ± 0.3°C at the level of the electronics and 22.2 ± 0.3°C on the interior surface of the helmet.

Study treatments were self-administered as follows: The subject\'s head was self-positioned within the helmet, until a sensor triggered the start of therapy. There was no contact between the subject and the light-emitting device; only the light reaches the subject scalp. Treatment duration was set to 25 minutes. The lasers and LEDs automatically shut off after the treatment session was complete. All device function was controlled by a hand set that was actuated by the user subject once the power cord was plugged into a standard 120 volt outlet and the start button was pressed. All other functions were pre-programmed and automatic. A full set of user instructions accompanied each helmet. There was no pre or post treatment care required, only that subjects\' hair must be clean and not contain spray or gel fixative agents. No safety eyewear was required during the treatment sessions. A complete demonstration of the proper use of the helmet was provided to each subject at the time the test units were distributed. Periodic subject monitoring was conducted by telephone. Subjects were queried relative to their use of the device and for any possible side effects or adverse events.

The subjects returned at 16 weeks for follow up and post treatment photography of the previously marked area. The area was again trimmed and photographed using the same apparatus and photographic conditions as at the initial (baseline) visit. The images were processed, transmitted and analyzed in the same fashion as was the case for the pretreatment photographs.

One pre-treatment (baseline) and one post-treatment image were counted for each subject. The number of terminal hairs present in the masked area was counted and recorded.

Data analysis was conducted by a consulting statistician, who was provided the raw data and who was blinded as to identify the subjects and their individual treatments. The primary endpoint for evaluation was the percent increase in hair counts from baseline at the end of 16 weeks of treatment. The percent increase from baseline is to be obtained by the following formula:

A data pooling analysis was done to determine whether there was a site by treatment interaction in the percent increase. An analysis of variance was done with only site, treatment group, and site by treatment group interaction in the model and the interaction was not statistically significant. The data were pooled across both sites to arrive at an estimate of the effect for the primary endpoint. Univariate tests comparing the Sham and Active treatment groups were by Wilcoxon rank-sum tests, and an unequal variance *t*-test was performed.

RESULTS AND STATISTICAL ANALYSIS
================================

Study Site Subject Distribution
-------------------------------

The study was a blinded multicenter study. The study subjects were allocated to Active Treatment or Sham on a 1:1 basis at each of two study sites. The distribution of study subjects by random treatment assignment and study site are given in Table[1](#tbl1){ref-type="table"}.

###### 

Subjects, Treatment Assignments, and Study Sites

  Site    Sham (Placebo)   Active Treatment   Total
  ------- ---------------- ------------------ -------
  1       6                7                  13
  2       12               17                 29
  Total   18               24                 42

A total of 47 patients were enrolled in the study and completed baseline screening and photography. However, three subjects at site one and two subjects from site two withdrew from the study prior to the initiation of treatment. Thus there were 24 active treatment and 18 sham subjects available for analysis at the end of the study after 16 weeks of treatment.

There were no reported side effects or adverse events reported by any subject or site at any time during the conduct of the study.

Baseline Demographic Characteristics
------------------------------------

There was information gathered on three important demographic characteristics, subject age, subject Fitzpatrick Skin Type, and Ludwig--Savin Baldness Scale. The results of these characteristics by treatment group are presented in the Table[2](#tbl2){ref-type="table"}.

###### 

Baseline Demographic Characteristics by Treatment Group

  Characteristic                Sham (Placebo)    Active Treatment   *P*-value
  ----------------------------- ----------------- ------------------ -----------
  Age                                                                0.068
   Mean (SD) N                  51.00 (7.05) 18   46.29 (9.22) 24    
   Med (Min, Max)               53 (33, 60)       49 (26, 58)        
  Fitzpatrick Skin Type                                              0.582
   I n (%)                      3 (22.22)         4 (16.67)          
   II n (%)                     3 (16.67)         6 (25.00)          
   III n (%)                    12 (61.11)        12 (50.00)         
   IV n (%)                     0 (0.00)          2 (8.33)           
  Ludwig-Savin Baldness Scale                                        0.858
   I n (%)                      7 (33.33)         11 (45.83)         
   II n (%)                     11 (66.67)        13 (54.17)         

Note that age was not statistically significant by treatment group nor was it significant by study site (*P* = 0.0320). Neither Fitzpatrick skin type nor the Ludwig--Savin Baldness Scale differed by treatment group. Both study sites differed by Fitzpatrick Skin Type (*P* \< 0.001) and by Ludwig--Savin Baldness Scale (*P* \< 0.001).

Hair Counts and Photography
---------------------------

Photographs of the selected scalp site were taken prior to any treatment (baseline) and the same site was again photographed after the final treatment had been performed (post-treatment).

Examples of baseline (pre treatment) and final (post treatment) images are presented in [Figures 1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}. [Figure 1](#fig01){ref-type="fig"} demonstrates the results for typical patients in the placebo or sham group. Note that there is only a slight change present in the images taken at 16 weeks as compared to the baseline images. [Figure 2](#fig02){ref-type="fig"} demonstrates baseline and final images for typical subjects in the active treatment group. A significant increase in the number of terminal hairs present is evident in the 16 week photographs compared to baseline. The diameter of the hairs present in the sample areas was not measured.

![Sham treatment group subject pre and post treatment image examples. Hair counts for subject A were 151 at baseline and 166 post treatment. Hair counts for subject B were 41 at baseline and 44 post treatment.](lsm0046-0601-f1){#fig01}

![Active treatment group subject pre and post treatment image examples. Hair counts for subject A were 153 at baseline and 221 post treatment. Hair counts for subject B were 108 at baseline and 209 post treatment.](lsm0046-0601-f2){#fig02}

Baseline Hair Counts
--------------------

The analyses reported below were conducted in Minitab 16 (Minitab, Inc, State College, PA). The raw data for these analyses appear in Appendix 1.

The baseline hair counts by treatment group and study site are presented in Table[3](#tbl3){ref-type="table"}. While the two study sites differ in the absolute values for the mean baseline hair counts, there was no statistical difference between the mean hair counts in the active and sham group subjects at the particular study center. An analysis of variance was done with only site, treatment group, and site by treatment group interaction in the model and the interaction was not statistically significant (*P* = 0.812).The study site was used as a possible covariate in the multivariable analyses performed below.

###### 

Baseline Hair Counts of Vertex Scalp Site

  Site        Sham (Placebo), Mean (SD) N, Med (Min, Max)   Active Treatment, Mean (SD) N, Med (Min, Max)   *P*-value
  ----------- --------------------------------------------- ----------------------------------------------- ---------------------------------------
  1           317.5 (174.1) 6, 277 (130, 560)               335.4 (144.6) 7, 260.0 (244, 599)               0.846[a](#tf3-1){ref-type="table-fn"}
  2           183.5 (84.9) 12, 201.5 (41, 327)              157.8 (50.5) 17, 152.0 (53, 234)                0.361[](#tf3-1){ref-type="table-fn"}
  *P*-Value   0.125[a](#tf3-1){ref-type="table-fn"}         0.019[a](#tf3-1){ref-type="table-fn"}           ---

Two-sided unequal variance *t*-test.

Primary Analysis
----------------

The primary endpoint was the percent increase in hair counts from baseline at the end of 16 weeks of treatment (60 treatments). The percent increase from baseline was obtained for each subject by using the formula above.

A data pooling analysis was done to determine if there was a site by treatment interaction in the percent increase. If the interaction between site and treatment was significant with a *P* \< 0.15, there would be evidence of a site by treatment interaction that would require weighting the site results to get an estimate of the study effect. An analysis of variance was done with only site, treatment group, and site by treatment group interaction in the model and the interaction was not statistically significant (*P* = 0.812). Thus the data were pooled across both sites to arrive at an estimate of the effect for the primary endpoint.

Univariate tests comparing the Sham and Active Treatment groups were intended to be by Wilcoxon rank-sum tests unless the variance between the two groups was statistically significantly different. In that case, the comparison was to be conducted by an unequal variance *t*-test. The results of the pooled data analysis appear in Table[4](#tbl4){ref-type="table"}.

###### 

Baseline Hair Counts, End of Study Hair Counts, and Percent Increase by Treatment Group

  Variable                   Sham (Placebo), Mean (SD) N, Med (Min, Max)   Active Treatment, Mean (SD) N, Med (Min, Max)   *P*-value
  -------------------------- --------------------------------------------- ----------------------------------------------- ----------------------------------------------
  Baseline                   228.2 (133.4) 18, 216.5 (41, 560)             209.6 (118.5) 24, 187.5 (53, 599)               0.642[a](#tf4-1){ref-type="table-fn"}
  Post Treatment             252.1 (143.3) 18, 248.0 (44, 636)             309.9 (166.6) 24, 270.5 (57, 829)               0.235[a](#tf4-1){ref-type="table-fn"}
  Difference from Baseline   23.9 (30.1) 18, 15.5 (-23, 108)               100.3 (53.4) 24, 91.0 (4, 230)                  **\<0.0001**[a](#tf4-1){ref-type="table-fn"}
  Percent Increase           11.05 (48.30) 18, 10.15 (-4.66, 43.20)        48.07 (17.61) 24, 45.58 (7.55, 93.52)           **\<0.001**[a](#tf4-1){ref-type="table-fn"}

Two-sided unequal variance *t*-test.

These results indicate that the univariate result comparing the increase in hair counts was statistically significant (*P* = 0.001). Low level laser treatment for 16 weeks increased mean hair counts by about 37% relative to sham treatment using the study device and the study treatment parameters. A multivariable analysis accounting for baseline differences in hair counts by study site indicates that the percent increase by treatment adjusted for study site indicate that the study site had a non-significant impact on the percent (*P* = 0.218). Therefore the study site differences in baseline counts did not modify the effect of treatment on the percent increase in hair counts after treatment. A second supportive multivariable analysis used baseline count as a covariate and in that analysis, the baseline term was not significant (*P* = 0.627), treatment was highly significant (*P* \< 0.0001), but study site was not statistically significant (*P* = 0.219). Further, when age, Fitzpatrick type and Ludwig--Savin scale were included in a third sensitivity model, none were statistically significant with *P*-values of 0.901, 0.939, and 0.538, respectively. Thus, the univariate result is confirmed by the multivariable analysis with active LLLT treatment as the only significant term in the model (*P* \< 0.001).

DISCUSSION
==========

Treatment of androgenetic alopecia with LLLT has been studied in humans and in animal models using a variety of light sources, wavelengths and treatment parameters [@b6]--[@b9],[@b11],[@b12],[@b14]--[@b16],[@b18]. We previously reported the results of the TH655 RCT using the so-called TOPHAT 655 device in males with androgenetic alopecia [@b16].

The present study details the results of the female arm of the same study protocol, which was initiated and completed after the male study was concluded. These investigations employed a randomized, double-blind design and used a true placebo via a helmet identical in appearance to the active device, with incandescent sources that glowed red but did not deliver measurable light to the subject\'s scalp and which operated at a temperature of 22.2 ± 0.3°C. Neither the active nor the sham devices delivered thermal energy to the scalp. Treatments were passive and did not depend on the user for delivery, aside from the subject being required to place the unit on the scalp and activate the controller.

Increases in hair counts were also observed in the sham or placebo group in the present study as was also the case in the earlier male cohort [@b16]. These observations may represent a true placebo effect, since the sham device did not deliver thermal energy or measurable light at scalp level. However, seasonal variations in hair growth or other factors could be the basis for this observation.

Avci et al. recently reviewed the use of LLLT for the treatment of hair loss [@b18]. They note that phototherapy is assumed to stimulate anagen re-entry in telogen hair follicles, prolong the duration of the anagen phase, increase the rates of proliferation in active anagen hair follicles and prevent premature catagen development [@b18]. They discuss several possible mechanisms for the photobiomodulation effect observed in these cases [@b18].

One such theory is that LLLT, particularly at wavelengths in the red range as was used in this investigation, affects the functioning of the stem cells that cause hair growth [@b16],[@b18]. LLLT activates cytochrome c oxidase and increases mitochondrial electron transport [@b19]--[@b27], which leads to an increase in ATP and subsequent reversal of hair follicles from the dormant telogen stage of growth, to the active growth or anagen stage [@b6],[@b7],[@b9],[@b11],[@b13],[@b14],[@b16],[@b18].

There is a growing body of evidence that the use of LLLT for the purpose of promoting hair growth is both safe and effective in both men and women. The optimal wavelengths and treatment parameters for treatment of alopecia remain indeterminate at this time. There is a need to conduct further studies in order to determine the potential role for near infrared and/or combinations of wavelengths as well as to investigate the effects of parameters such as coherence, pulsing and treatment frequency on clinical outcomes. The present study was not designed to investigate alternative treatment regimes or parameters. It was designed to evaluate the safety and effectiveness of a particular device designed for home use with specific parameters on the treatment of women with androgenetic alopecia.

We have demonstrated that the use of low level laser therapy at 655 nm applied to the scalp every other day for 16 weeks (60 treatments) via the TOPHAT 655 device resulted in a significant improvement in women who used the device. There was a 37% increase in terminal hair counts in the active treatment group as compared to the control (sham) group (*P* \< 0.001) in 18--60 year old female subjects with I-2, I-3, I-4, II-1, or II-2 Ludwig--Savin baldness patterns and Fitzpatrick I--IV Skin Types. These results mirror those of the previously reported male trial which demonstrated a 35% increase in males with Hamilton--Norwood IIa-V baldness patterns and Type I--IV Fitzpatrick Skin Types [@b16].

Similarly, the female subjects were able to conduct the treatments at home and were able to apply and use the device as directed without any side effects or adverse events being reported at any time during the conduct of the study. This indicates that the device is safe for the unsupervised environment of home use and that the therapy is easily managed by both men and women using this device.

SUMMARY
=======

The present study demonstrates that that low level laser (light) treatment of the scalp every other day for 16 weeks using the TOPHAT 655 device is a safe and effective treatment for androgenic alopecia in healthy women between the ages of 18--60 with Fitzpatrick Skin Types I--IV and Ludwig--Savin Baldness Scale I-2--II-2 baldness patterns. Subjects receiving LLLT at 655 nm achieved a 37% increase in hair counts as compared to sham treated control patients in this multicenter RCT. These results are similar to those reported in an earlier study using the same device in males with alopecia.

###### 

Raw Hair Counts by Study Site and Treatment Group.

  Subject[a](#tfA-1){ref-type="table-fn"}   Site   Treatment   Age (yrs)   Fitzpatrick Skin Type   Ludwig Savin Scale   BaselineHair Count   Posttrt[b](#tfA-2){ref-type="table-fn"}   Diff[c](#tfA-3){ref-type="table-fn"}   Pct_bas[d](#tfA-4){ref-type="table-fn"}
  ----------------------------------------- ------ ----------- ----------- ----------------------- -------------------- -------------------- ----------------------------------------- -------------------------------------- -----------------------------------------
  1                                         1      Active      43          1                       I                    483                  687                                       204                                    42.236
  2[\*](#tfA-4){ref-type="table-fn"}        1      ---         27          1                       II                                                                                                                         
  3                                         1      Sham        57          3                       I                    292                  297                                       5                                      1.712
  4[\*](#tfA-4){ref-type="table-fn"}        1      ---         45          1                       I                                                                                                                          
  5                                         1      Sham        44          2                       I                    494                  471                                       −23                                    −4.656
  6                                         1      Active      52          1                       I                    245                  333                                       88                                     35.918
  7                                         1      Active      57          1                       I                    244                  358                                       114                                    46.721
  8[\*](#tfA-4){ref-type="table-fn"}        1      ---         49          3                       I                                                                                                                          
  9                                         1      Sham        57          1                       II                   130                  150                                       20                                     15.385
  10                                        1      Active      50          1                       II                   249                  334                                       85                                     34.137
  11                                        1      Sham        33          1                       I                    560                  636                                       76                                     13.571
  12                                        1      Sham        58          3                       II                   262                  311                                       49                                     18.702
  13                                        1      Active      52          3                       II                   268                  450                                       182                                    67.910
  14                                        1      Active      52          2                       I                    260                  354                                       94                                     36.154
  15                                        1      Active      44          2                       I                    599                  829                                       230                                    38.397
  16                                        1      Sham        53          1                       II                   167                  170                                       3                                      1.796
  17                                        2      Active      44          3                       I                    228                  375                                       147                                    64.474
  18                                        2      Active      51          3                       II                   234                  385                                       151                                    64.530
  19                                        2      Active      50          3                       II                   145                  221                                       76                                     52.414
  20                                        2      Active      47          3                       I                    182                  276                                       94                                     51.648
  21                                        2      Active      33          3                       II                   153                  221                                       68                                     44.444
  22                                        2      Active      26          3                       II                   192                  263                                       71                                     36.979
  23                                        2      Active      56          3                       II                   148                  203                                       55                                     37.162
  24                                        2      Active      45          2                       I                    108                  209                                       101                                    93.519
  25                                        2      Active      44          3                       II                   53                   57                                        4                                      7.547
  26                                        2      Active      38          2                       II                   144                  230                                       86                                     59.722
  27                                        2      Active      51          3                       II                   152                  265                                       113                                    74.342
  28                                        2      Active      58          2                       II                   110                  139                                       29                                     26.364
  29                                        2      Active      53          3                       II                   225                  340                                       115                                    51.111
  30                                        2      Active      58          3                       I                    97                   146                                       49                                     50.515
  31                                        2      Sham        60          3                       I                    41                   44                                        3                                      7.317
  32                                        2      Sham        51          3                       I                    224                  248                                       24                                     10.714
  33                                        2      Sham        59          3                       II                   116                  140                                       24                                     20.690
  34                                        2      Sham        45          2                       II                   209                  249                                       40                                     19.139
  35                                        2      Sham        46          3                       I                    327                  342                                       15                                     4.587
  36                                        2      Sham        54          3                       II                   250                  358                                       108                                    43.200
  37                                        2      Sham        53          3                       II                   135                  149                                       14                                     10.370
  38                                        2      Sham        42          3                       II                   232                  248                                       16                                     6.897
  39[\*](#tfA-4){ref-type="table-fn"}       2      ---         20          3                       I                                                                                                                          
  40                                        2      Sham        53          3                       II                   262                  270                                       8                                      3.053
  41                                        2      Sham        52          3                       I                    61                   60                                        −1                                     −1.639
  42                                        2      Active      28          4                       I                    204                  328                                       124                                    60.784
  43                                        2      Sham        55          2                       II                   151                  166                                       15                                     9.934
  44[\*](#tfA-4){ref-type="table-fn"}       2      ---         27          3                       II                                                                                                                         
  45                                        2      Sham        46          3                       II                   194                  229                                       35                                     18.041
  46                                        2      Active      31          4                       I                    183                  264                                       81                                     44.262
  47                                        2      Active      48          2                       II                   124                  171                                       47                                     37.903

Patient numbers were grouped for convenience not by order of presentation or randomization.

Psttrt is the hair count after 16 weeks of treatment.

Diff = Psttrt -- Baseline Hair Count.

Pct_bas is the percent hair increase (decrease) at 16 weeks as a percent of baseline.

Five subjects withdrew from the study after enrollment and prior to treatment.
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